Arrowhead Pharma in License Agreement With GSK for ARO-HSD
November 22 2021 - 3:55PM
Dow Jones News
By Stephen Nakrosis
Arrowhead Pharmaceuticals Inc. on Monday said it entered an
exclusive license agreement with GlaxoSmithKline which will see GSK
develop and commercialize Arrowhead's ARO-HSD.
Arrowhead said ARO-HSD is an "investigational RNA interference
therapeutic in a Phase 1/2 trial that is currently being developed
as a treatment for patients with nonalcoholic steatohepatitis."
Arrowhead will receive an upfront payment of $120 million.
Arrowhead is also eligible for additional payments tied to future
trials and regulatory approval, as well as for commercial milestone
payments and royalties, according to the companies.
GlaxoSmithKline will receive an exclusive license to develop and
commercialize ARO-HSD in all territories except Greater China,
which will be retained by Arrowhead, the companies said.
The deal is expected to close in the first quarter of next
year.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
November 22, 2021 16:40 ET (21:40 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Historical Stock Chart
From Apr 2024 to May 2024
Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Historical Stock Chart
From May 2023 to May 2024